1
Kevin Rodzinak
Mark E Layton, Kevin J Rodzinak, Michael J Kelly, Philip E Sanderson: 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists. Merck And Co, December 20, 2007: US20070293515-A1

Compounds represented by Formula I: (wherein A, B, D, P, Q, R1, R2, R3, W and Y are described herein) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, ...


2
Chakravarty Prasun K, Greenlee William J, Mantlo Nathan B, Patchett Arthur A, Walsh Thomas F: Substituted imidazo-fused 6-membered heterocycles as angiotensin ii antagonists.. Merck & Co, December 5, 1990: EP0400974-A2 (191 worldwide citation)

Substituted Imidazo-fused 6-membered heterocycles of structural formula: wherein A, B, C, and D are independently carbon atoms or nitrogen atoms are angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure.


3
Oshlack Benjamin, Chasin Mark: Orally administrable opioid formulations having extended duration of effect.. Euro Celtique, April 12, 1995: EP0647448-A1 (161 worldwide citation)

Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates includin ...


4
Emonds Alt Xavier, Goulaouic Pierre, Proietto Vincenzo, Van Broeck Didier: Compounds of aromatic amines and their enantiomers, process for their preparation and pharmaceutical compositions containing them.. Sanofi, May 22, 1991: EP0428434-A2 (138 worldwide citation)

The invention relates to compounds of formula in which: - m is an integer from 1 to 3; - Ar and Ar' represent, independently, a thienyl group, a substituted or unsubstituted phenyl group; an imidazolyl group; it also being possible for Ar' to be a benzothienyl group, unsubstituted or substituted wit ...


5
Morella Angel Mario, Fisher Mark Christopher: Sustained release pharmaceutical composition.. Faulding F H &, July 11, 1990: EP0377518-A2 (118 worldwide citation)

A sustained release pharmaceutical pellet composition suitable for treating pain-associated conditions in patients comprises a core element including at least one active ingredient of high solubility; and a core coating for the core element which is partially soluble at a highly acidic pH to provide ...


6
Strupczewski Joseph T, Helsley Grover C, Chiang Yulin, Bordeau Kenneth J: (aryloxyalkyl)Heteroarylpiperidines and -heteroarylpiperazines,a process for their preparation and their use as medicaments.. Hoechst Roussel Pharma, December 19, 1990: EP0402644-A1 (106 worldwide citation)

This invention related to compounds of the formula: wherein X is -O-, -S-, - @H, or -@-R; p is 1 or 2; Y is hydrogen, C1 to C6 alkyl, -OH, Cl, F, Br, I, C1 to C6 alkoxy, -CF3, NO2, or -NH2, when p is 1; Y is C1 to C6 alkoxy when p is 2 and X is -O-; R is selected from the group consisting of lower a ...


7
Oshlack Benjamin: Controlled release bases for pharmaceuticals.. Euro Celtique, January 20, 1988: EP0253104-A1 (105 worldwide citation)

The release of therapeutically active agents from controlled release bases is extended by using a combination of a higher aliphatic alcohol and an acrylic resin as the base material.


8
Strupczewski Joseph T: 3-(piperidinyl)- and 3-(pyrrolidinyl)-1h-indazoles, a process for their preparation and their use as a medicament.. Hoechst Roussel Pharma, April 3, 1985: EP0135781-A1 (103 worldwide citation)

Novel 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles, intermediates and processes for the preperation thereof, and their use for treating psychoses and alleviating pain are disclosed.


9
Chen Yuhpyng L: Substituted heterocyclic derivatives as crf antagonists. Pfizer, June 11, 1997: EP0778277-A1 (101 worldwide citation)

Corticotropin-releasing factor (CRF) antagonists having the formula or wherein the dashed lines, A, B, D, E, F, Z, G, R, and R are as defined below, and pharmaceutical compositions containing them.


10
Barth Francis Res Saint James, Casellas Pierre, Congy Christian, Martinez Serge, Rinaldi Murielle, Anne Archard Gilles: Substituted n-piperidino 3-pyrazolecarboxamide.. Sanofi, June 7, 1995: EP0656354-A1 (99 worldwide citation)

N-Piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyra zole-3-carboxamide of formula: its salts and solvates are powerful antagonists of central cannabinoid receptors. They are prepared by reaction of a functional derivative of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole- ...